Fluor Corporation announced recently that it has been awarded a $487 million biotech expansion project in Denmark and is also mobilizing resources in the central U.S. for the first phase of a new life sciences production facility valued at $574 million. Fluor will recognize these reimbursable contracts in the second quarter backlog.

 

“We are excited to see the significant investments being made globally in the production of cutting-edge technologies and pharmaceuticals that will improve the lives of billions of people,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business. “Delivering these projects will help to increase the speed-to-market and meet the overwhelming demand for new medicines.”